Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch

This article was originally published in The Pink Sheet Daily

Executive Summary

Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
Advertisement

Related Content

Forest Credits Lexapro Growth To Less Detailing By Competitors
Forest Credits Lexapro Growth To Less Detailing By Competitors
Combunox's Future At Forest May Depend On Success Of New Trial Program
Combunox's Future At Forest May Depend On Success Of New Trial Program
Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth
Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
Lexapro, Namenda Inventory Workdowns Cut Forest's Fourth Quarter Sales
Lilly Rebuts Lexapro Onset To Efficacy Claim
Lilly Rebuts Lexapro Onset To Efficacy Claim

Topics

Advertisement
UsernamePublicRestriction

Register

PS061110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel